179064-48-3Relevant academic research and scientific papers
Synthesis and optimization of novel 4,4-disubstituted cyclohexylbenzamide derivatives as potent 11β-HSD1 inhibitors
Sun, Daqing,Wang, Zhulun,Caille, Seb,Degraffenreid, Michael,Gonzalez-Lopez De Turiso, Felix,Hungate, Randall,Jaen, Juan C.,Jiang, Ben,Julian, Lisa D.,Kelly, Ron,McMinn, Dustin L.,Kaizerman, Jacob,Rew, Yosup,Sudom, Athena,Tu, Hua,Ursu, Stefania,Walker, Nigel,Willcockson, Maren,Yan, Xuelei,Ye, Qiuping,Powers, Jay P.
body text, p. 405 - 410 (2011/02/27)
The synthesis and SAR of a series of 4,4-disubstituted cyclohexylbenzamide inhibitors of 11β-HSD1 are described. Optimization rapidly led to potent, highly selective, and orally bioavailable inhibitors demonstrating efficacy in both rat and non-human primate ex vivo pharmacodynamic models.
Potent bradykinin B1 receptor antagonists: 4-Substituted phenyl cyclohexanes
Su, Dai-Shi,Lim, John L.,Markowitz, M. Kristine,Wan, Bang-Lin,Murphy, Kathy L.,Reiss, Duane R.,Harrell, C. Meacham,O'Malley, Stacy S.,Ransom, Rick W.,Chang, Raymond S.L.,Pettibone, Douglas J.,Tang, Cuyue,Prueksaritanont, Thomayant,Freidinger, Roger M.,Bock, Mark G.
, p. 3006 - 3009 (2008/02/04)
Selective bradykinin (BK) B1 receptor antagonists have been shown to be antinociceptive in animal models and could be novel therapeutic agents for the treatment of pain and inflammation. Elucidation of the structure-activity relationships of the biphenyl moiety of the lead compound 1 provided a potent new structural class of BK B1 receptor antagonists.
